ATE313561T1 - Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen - Google Patents

Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen

Info

Publication number
ATE313561T1
ATE313561T1 AT00947543T AT00947543T ATE313561T1 AT E313561 T1 ATE313561 T1 AT E313561T1 AT 00947543 T AT00947543 T AT 00947543T AT 00947543 T AT00947543 T AT 00947543T AT E313561 T1 ATE313561 T1 AT E313561T1
Authority
AT
Austria
Prior art keywords
vgf
methods
polypeptides
diseases
treating
Prior art date
Application number
AT00947543T
Other languages
English (en)
Inventor
Hai Yan
Thomas C Boone
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE313561T1 publication Critical patent/ATE313561T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
AT00947543T 1999-07-21 2000-07-19 Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen ATE313561T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14479799P 1999-07-21 1999-07-21
PCT/US2000/019701 WO2001007477A1 (en) 1999-07-21 2000-07-19 Vgf polypeptides and methods of treating vgf-related disorders

Publications (1)

Publication Number Publication Date
ATE313561T1 true ATE313561T1 (de) 2006-01-15

Family

ID=22510177

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00947543T ATE313561T1 (de) 1999-07-21 2000-07-19 Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen

Country Status (10)

Country Link
EP (1) EP1196442B1 (de)
JP (2) JP2003505471A (de)
AT (1) ATE313561T1 (de)
AU (1) AU783199B2 (de)
CA (1) CA2380037A1 (de)
DE (1) DE60024997T2 (de)
DK (1) DK1196442T3 (de)
ES (1) ES2255502T3 (de)
MX (1) MXPA02000680A (de)
WO (1) WO2001007477A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029840A1 (en) * 2004-09-14 2006-03-23 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
GB0502979D0 (en) * 2005-02-14 2005-03-16 Univ Cambridge Tech Biomarkers and uses thereof
JPWO2006118313A1 (ja) * 2005-04-27 2008-12-18 武田薬品工業株式会社 新規ポリペプチドおよびその用途
EP1939286A4 (de) * 2005-07-29 2009-05-20 Kyowa Hakko Kirin Co Ltd Neue peptide
JPWO2007105442A1 (ja) * 2006-02-22 2009-07-30 協和発酵キリン株式会社 摂食障害または摂水障害の治療薬
EP2123751A4 (de) * 2007-01-25 2010-06-02 Kyowa Hakko Kirin Co Ltd Neues peptid
MX2011013898A (es) 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
US8940878B2 (en) * 2009-06-25 2015-01-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2380920A1 (de) 2010-04-22 2011-10-26 QGel SA Hydrogelvorstufenformulierung und Herstellungsverfahren dafür
JP5914906B2 (ja) * 2010-12-28 2016-05-11 国立大学法人 宮崎大学 インスリン分泌促進剤
KR102505358B1 (ko) 2020-01-06 2023-03-06 재단법인 아산사회복지재단 Vgf 유래 펩티드를 포함하는 골 질환의 예방 또는 치료용 조성물
WO2021141355A1 (ko) * 2020-01-06 2021-07-15 재단법인 아산사회복지재단 Vgf 유래 펩티드를 포함하는 골 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2001007477A1 (en) 2001-02-01
AU783199B2 (en) 2005-10-06
DK1196442T3 (da) 2006-05-08
AU6112700A (en) 2001-02-13
MXPA02000680A (es) 2002-07-02
EP1196442A1 (de) 2002-04-17
DE60024997D1 (de) 2006-01-26
JP2006176528A (ja) 2006-07-06
CA2380037A1 (en) 2001-02-01
JP2003505471A (ja) 2003-02-12
ES2255502T3 (es) 2006-07-01
DE60024997T2 (de) 2006-08-24
EP1196442B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
AU2002305450A1 (en) Proteomimetic compounds and methods
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196442

Country of ref document: EP

REN Ceased due to non-payment of the annual fee